RNS Number : 3219Z
OptiBiotix Health PLC
14 September 2022

OptiBiotix Health plc
("OptiBiotix" or the "Company")

New commercialisation partner in Asia Pacific

OptiBiotix Ltd, a wholly owned subsidiary of OptiBiotix Health plc (AIM: OPTI) and a life sciences business developing patented science and human study-based compounds that modulate the microbiome to address a range of health related issues such as metabolic syndrome and diabetes, systemic low-grade inflammation, obesity, cardiovascular disease, high cholesterol and healthy aging announces it has signed a services agreement with Nutraconnect for the Asia Pacific ("APAC") Region. Nutraconnect will develop and implement the go-to-market strategy for prebiotics ingredients SlimBiome® and LeanBiome®.

Nutraconnect Pte., Ltd. ("Nutraconnect"), is a nutraceutical business growth acceleration service headquartered in Singapore. The company provides end-to-end solutions for global nutraceutical ingredient manufacturers that are looking to establish a foundation for sustainable growth in the fragmented but growing APAC market. Nutraconnect possesses a wealth of experience in bringing innovative and science backed nutraceutical ingredients successfully to the market in the region.

René Kamminga, CEO of OptiBiotix Limited, commented: *"*Nutraconnect *is an important extension of our commercial experience and reach in the APAC region.* Nutraconnect *brings unique regulatory and commercial experience combined with an extensive distribution and agency network in the various countries in the region. This partnership will help expedite the commercialisation of our prebiotic technologies in strategic countries in the region. At the same time, it will allow OptiBiotix to focus primarily on established key accounts and building up our North American presence and sales."*

The Directors of the Company are responsible for the release of this announcement.

For further information, please contact:

OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive *Contact via Walbrook below*

Cenkos Securities plc (Broker) Tel: 020 7397 8900
Callum Davidson / Neil McDonald
Michael Johnson / Russell Kerr (Sales)

Walbrook PR Ltd Mob: 07876 741 001
Anna Dunphy

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

This communication is a "Reach" announcement. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRABKNBQQBKDBCD